Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: a pilot randomized controlled trial
- 15 September 2011
- journal article
- research article
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 33 (1) , 88-94
Abstract
There is a need for more effective therapies to reduce morbidity and mortality from cardiovascular disease. Inflammation plays a central role in the pathogenesis of atherosclerosis but no randomized studies have evaluated anti-inflammatory therapy in patients with acute coronary or cerebrovascular disease. We performed a pilot randomized controlled trial comparing the effect of colchicine 1 mg per day with placebo on high sensitivity C-reactive protein (CRP) levels and platelet function in 80 patients with acute coronary syndrome or acute ischemic stroke who were followed for 30 days. Clinical status was ascertained for 74 (92.5%) patients and CRP levels were obtained in 68 (85%) of patients at follow up. Colchicine did not significantly reduce absolute hs-CRP at 30 days [median 1.0 mg/l (range 0.2, 162.0) versus 1.5 mg/l (0.2, 19.8), P = 0.22] or difference in CRP from baseline to 30 days [absolute difference 7.0 mg/l (−61.0, 87.8) vs. 7.1 mg/l (−1.0, 144), P = 0.64]. The proportion of patients with CRP X 2 1.84, P = 0.18). There was also no difference in platelet function assessed using platelet aggregation with ADP (5 μmol), arachidonic acid (0.5 mmol), collagen (1 μg/ml) and collagen (5 μg/ml) (P = 0.86, P = 0.64, P = 0.76, P = 0.20, respectively), and urine dehydrothromboxane B2 (P = 0.54). Colchicine was associated with an excess of diarrhoea (X 2 4.14, P = 0.04). In conclusion, our pilot study provided no evidence that colchicine 1 mg daily for 30 days compared with placebo suppresses inflammation in patients with acute coronary syndrome or acute ischemic stroke.Keywords
This publication has 15 references indexed in Scilit:
- C-Reactive Protein as a Risk Factor for Coronary Heart Disease: A Systematic Review and Meta-analyses for the U.S. Preventive Services Task ForceAnnals of Internal Medicine, 2009
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinNew England Journal of Medicine, 2008
- Effect of Colchicine (0.5 mg Twice Daily) on High-Sensitivity C-Reactive Protein Independent of Aspirin and Atorvastatin in Patients With Stable Coronary Artery DiseaseThe American Journal of Cardiology, 2007
- Pathology of the Vulnerable PlaqueJACC, 2006
- C-Reactive Protein Levels and Outcomes after Statin TherapyNew England Journal of Medicine, 2005
- C-Reactive Protein and Other Inflammatory Biomarkers as Predictors of Outcome Following Acute Coronary SyndromesSeminars in Vascular Medicine, 2003
- Inflammatory Markers of Coronary RiskNew England Journal of Medicine, 2000
- Markers of Myocardial Damage and Inflammation in Relation to Long-Term Mortality in Unstable Coronary Artery DiseaseNew England Journal of Medicine, 2000
- Extracellular Matrix Modulates Macrophage Functions Characteristic to AtheromaArteriosclerosis, Thrombosis, and Vascular Biology, 1998
- Effect of mitosis inhibitors on blood platelet microtubules and aggregationThe Journal of Physiology, 1971